InCarda Therapeutics, a biopharmaceutical company out of Palo Alto, CA, discovered a faster and more effective way to treat cardiovascular disease: via the inhalation route. This novel approach brings a huge advantage – it offers a lower dose, with more control, ensuring the effects are extremely targeted and patients are not over-exposed to the drug. When we met, InCarda was riding strong momentum from a Series A round of funding. They were looking to gear up for a Series B and release to a wider audience which included future investors, Key Opinion Leaders (KOLs) and potential partners.
The mission was to evolve their brand to better align with the team’s first-rate credentials and position them as leaders in their field. InCarda handed us their entire marketing platform. We began working closely with the executive team to map out their identity and craft compelling messaging around key competitive advantages and benefits for both their investor and institutional audiences.
“I cannot say enough good things about the whole experience working with ID. The value of our partnership goes well beyond content and design elements. I liked the way they became a strategic partner for InCarda – as a startup, we needed a more integrated, comprehensive approach. I’ve already recommended ID to several people, and the team is currently working with a couple of my collaborator companies.”- Grace Colon, Chief Executive Officer
By creating a messaging platform that is scientifically cutting edge, while remaining consumer-friendly, we successfully built a brand that showcases InCarda’s novel delivery method, communicates their competitive advantage and outlines the unique market opportunity. As a result, 2016 has a positive outlook; The InCarda team is on their way to Series B this year, attracting new and diverse investors, they are rolling out new products and adding to their pipeline and they are expanding their management team and advisory board with key members.